Takeda Pharmaceutical Company Ltd
πΈπͺSweden
- Country
- πΈπͺSweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease
Phase 2
Withdrawn
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: MLN1202Drug: Placebo
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Takeda
- Registration Number
- NCT02388971
Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-058Drug: TAK-058 Placebo
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT02389881
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 481
- Registration Number
- NCT02388724
- Locations
- π°π·
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
π°π·Asan Medical Center, Seoul, Korea, Republic of
π°π·The Catholic University of Korea, Seoul St. Marys Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 703
- Registration Number
- NCT02388737
- Locations
- π²πΎ
University Malaya Medical Centre, Kuala Lumpur, Malaysia
π¨π³Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
π¨π³Taipei Medical University Hospital, Taipei City, Taiwan
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Febuxostat XRDrug: Maalox Advance Regular Strength liquid
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT02382640
Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 17
- Registration Number
- NCT02381288
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 108
- Registration Number
- NCT02379091
Food Effect Study of Febuxostat XR in Healthy Participants
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT02374164
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1106
- Registration Number
- NCT02371980
- Locations
- πΊπΈ
Atlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈJanice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach, West Palm Beach, Florida, United States
πΊπΈCollaborative Neuroscience Network, LLC, Torrance, California, United States
A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SYR-472
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02372097
Β© Copyright 2025. All Rights Reserved by MedPath